Appendix 4D and Half Year Financial Report
Filed with ASX · · 24 pages · English
Summary by 6ix AI
The report indicates a significant increase in revenues from ordinary activities, while the company reported a loss attributable to its owners, which has also increased compared to the previous period. The financial statements were reviewed by auditors, who confirmed compliance with relevant accounting standards and noted a material uncertainty regarding the company's ability to continue as a going concern.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Dimerix
- Quarterly Appendix 4C and Activities Report
- BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
- DMX-200 ACTION3 Phase 3 trial completes recruitment
- Successful Completion of Planned IDMC Review
- Successful PARASOL Collaboration Data Analysis Outcome
Later from Dimerix
- Dimerix Phase 3 Trial Last Patient Receives First Dose
- Dimerix to Conduct Review of ACTION3 Statistical Assumptions
- ACTION3 Statistical Review Complete
- Blinded assessment of ACTION3 statistical assumptions complete
- Dimerix Quarterly Activities Report and Appendix 4C
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix